Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 2/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4890479 | 0.82 | HRH1 (0.39) | TAAR1HTR2ADPP4TSHRF2 | |
| SCHEMBL4126387 | 0.79 | TAAR1 (0.44) | TAAR1HTR2ADPP4TSHRF2 | |
| SCHEMBL4890470 | 0.79 | HRH1 (0.39) | TAAR1HTR2ADPP4TSHRF2 | |
| SCHEMBL1538461 | 0.78 | TAAR1 (0.42) | TAAR1HTR2ADPP4TSHRF2 | |
| SCHEMBL94275 | 0.77 | HTR2A (0.52) | TAAR1HTR2ADPP4TSHRF2 | |
| SCHEMBL9350831 | 0.76 | HTR2A (0.40) | TAAR1HTR2ADPP4TSHRF2 | |
| SCHEMBL15560207 | 0.76 | TSHR (0.43) | TAAR1HTR2ADPP4TSHRF2 | |
| SCHEMBL3898638 | 0.76 | LMNA (0.52) | TAAR1HTR2AHRH1LMNA | |
| SCHEMBL17816146 | 0.76 | LMNA (0.52) | TAAR1HTR2AHRH1LMNA | |
| SCHEMBL5597894 | 0.76 | TRPA1 (0.45) | TAAR1HTR2ADPP4TSHRF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115380211-A | Refining process and refined product | 日本水产株式会社 | 2022-11-22 | — | — | CN | claimed |
| CN-105102456-B | Azaquinazoline inhibitors of atypical protein kinase C | 癌症研究技术有限公司 | 2017-11-14 | — | — | CN | claimed |
| CN-101180266-A | Alpha ketoamide compounds as cysteine protease inhibitors | APPLERA CORP (US) | 2008-05-14 | — | — | CN | claimed |
| CN-1512983-A | Compounds and compositions as cathepsins inhibitors | AXYSҩ�﹫˾ | 2004-07-14 | — | — | CN | claimed |
| US-5461074-A | Dipropargyl containing aryl/alkyl sulfur/or sulfonyl/or sulfoxide terminated aminodiol compounds are used as renin inhibitor; therpeutical | G.D. SEARLE & CO. (US) | 1995-10-24 | — | — | US | claimed |
| US-5317039-A | Renin inhibitors with peptides | G. D. SEARLE & CO. (US) | 1994-05-31 | — | — | US | claimed |
| US-5314920-A | Renin inhibitors | G. D. SEARLE & CO. (US) | 1994-05-24 | — | — | US | claimed |
| US-5312838-A | β-alanineamide aryl/alkylsulfide/sulfonyl-terminated amino-diol compounds for treatment of hypertension | G. D. SEARLE & CO. (US) | 1994-05-17 | — | — | US | claimed |
| US-5268391-A | Cardiovascular disorders | C. D. SEARLE & CO. (US) | 1993-12-07 | — | — | US | claimed |
| US-5246969-A | Oligopeptides as renin inhibitors | G. D. SEARLE & CO. (US) | 1993-09-21 | — | — | US | claimed |
| WO-2024101336-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | 国立大学法人京都大学 | 2024-05-16 | — | — | WO | disclosed |
| US-20240075407-A1 | METHOD OF PURIFICATION AND PURIFIED PRODUCTS | NISSUI CORPORATION (JP) | 2024-03-07 | — | — | US | disclosed |
| CN-116830317-A | Positive electrode slurry and secondary battery prepared from same | 宁德时代新能源科技股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-116589494-A | Magnesium/calcium borate, and preparation method and application thereof | 浙江大学杭州国际科创中心 | 2023-08-15 | — | — | CN | disclosed |
| WO-2023097432-A1 | POSITIVE ELECTRODE SLURRY, AND SECONDARY BATTERY PREPARED THEREFROM | 宁德时代新能源科技股份有限公司 | 2023-06-08 | — | — | WO | disclosed |
| US-4420477-A | ANTIBIOTICS, BACTERICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-12-13 | — | — | US | disclosed |
| EP-0095029-A1 | 5-Thio-tetrazol compounds and their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-11-30 | — | — | EP | disclosed |
| US-4405617-A | ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-09-20 | — | — | US | disclosed |
| EP-0033965-A2 | New cephem compounds and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-08-19 | — | — | EP | disclosed |
| EP-0029998-A2 | Cephem compounds, processes for their preparation and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240075407-A1 | METHOD OF PURIFICATION AND PURIFIED PRODUCTS | SPOP, SSRP1, SPIN4 | TAAR1 4602/4885HTR2A 2537/4885DPP4 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.